Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system.
about
Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part II: development of a potent and highly selective M1 PAMBiased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR CurrentsThe antipsychotic potential of muscarinic allosteric modulationAllosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's diseaseAllosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders.Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents.Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100Targeting selective activation of M(1) for the treatment of Alzheimer's disease: further chemical optimization and pharmacological characterization of the M(1) positive allosteric modulator ML169.Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophreniaTargeting glutamate synapses in schizophreniaData regarding M1 muscarinic receptor-mediated modulation of hepatic catalase activity in response to oxidative stressChemical lead optimization of a pan G(q) mAChR M(1), M(3), M(5) positive allosteric modulator (PAM) lead. Part I: Development of the first highly selective M(5) PAM.Heterobiaryl and heterobiaryl ether derived M5 positive allosteric modulators.Molecular mechanisms of bitopic ligand engagement with the M1 muscarinic acetylcholine receptor2013 Philip S. Portoghese Medicinal Chemistry Lectureship: drug discovery targeting allosteric sites.Development of allosteric modulators of GPCRs for treatment of CNS disordersOpportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders.Mechanistic insights into allosteric structure-function relationships at the M1 muscarinic acetylcholine receptor.Muscarinic Acetylcholine Receptor Subtypes as Potential Drug Targets for the Treatment of Schizophrenia, Drug Abuse and Parkinson's DiseaseContribution of both M1 and M4 receptors to muscarinic agonist-mediated attenuation of the cocaine discriminative stimulus in mice.Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discoveryNovel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal modelsProtection Efficacy of the Extract of Ginkgo biloba against the Learning and Memory Damage of Rats under Repeated High Sustained +Gz Exposure.Classics in chemical neuroscience: clozapine.Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficitsMolecular determinants of allosteric modulation at the M1 muscarinic acetylcholine receptor.Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential.Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophreniaM1 muscarinic acetylcholine receptor in Alzheimer's diseaseDevelopment of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071.Diverse Effects on M1 Signaling and Adverse Effect Liability within a Series of M1 Ago-PAMs.Chemical modification of the M(1) agonist VU0364572 reveals molecular switches in pharmacology and a bitopic binding mode.Discovery of novel N-substituted oxindoles as selective m1 and m4 muscarinic acetylcholine receptors partial agonists.Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probe.Synthesis and Biological Evaluation of Cremastrine and an Unnatural Analogue.Further exploration of M₁ allosteric agonists: subtle structural changes abolish M₁ allosteric agonism and result in pan-mAChR orthosteric antagonism.Continued optimization of the MLPCN probe ML071 into highly potent agonists of the hM1 muscarinic acetylcholine receptor.Pharmacological characterization of M1 muscarinic acetylcholine receptor-mediated Gq activation in rat cerebral cortical and hippocampal membranes.Effects of muscarinic M1 and M4 acetylcholine receptor stimulation on extinction and reinstatement of cocaine seeking in male mice, independent of extinction learning.Cognition Enhancing and Neuromodulatory Propensity of Bacopa monniera Extract Against Scopolamine Induced Cognitive Impairments in Rat Hippocampus.
P2860
Q24631627-E8BA0116-F40B-4D35-A1DC-3A458644CBBEQ27305419-8FCA0045-24C9-4DC8-87C8-27002DFD97EBQ28603221-36C8C22A-77FF-4A55-9454-D714F2009BF3Q28660933-5A752D08-C8C9-4723-AF0F-07D8CC01763FQ30388923-F7729F6C-5B81-4B91-9705-1FCF76737537Q30406145-B497FEAE-AB0C-4276-BA72-DD9E83A0556CQ30410518-545AA78C-A37A-4909-B7B9-DFB21CB1569EQ30446914-89D251D6-B2E7-4F33-B177-07C45B42CB1AQ30459624-7905CAAD-04C1-4B1D-B492-B923E414B5D4Q30460392-50A24237-3D8E-4BA0-A8EF-14607D5BFE62Q31044070-25AECA9E-0C98-4157-9964-5B0931581A51Q33518105-6A953464-AC79-4A45-96D2-7719DE4E0C04Q34134678-5DCBD482-94C7-42B3-9BB3-D394956E4988Q34140989-88078EAF-B3C9-4A50-9B36-48623D3401B5Q34243209-1CACAED5-592E-4589-A493-8AE0D20DC5B7Q34373958-2043C581-86C5-4EDD-965C-0F4B2665A2F9Q34399823-B7551FDC-6063-4E0B-8867-C3A4E18F9D31Q34580443-B5C5187F-6540-444F-ACCA-05F3E81848DEQ35789730-0A76B569-C43E-4BBA-843C-A7E9671AA84DQ35857172-C9E123DE-B1F2-4D19-B9EA-8DDE3C66B72AQ35952381-CFDBDCD3-8763-4AF9-9875-9F58CD925294Q36099440-D4B1B5EE-929B-4FC1-AAFF-25A52FCF1F91Q36741440-3722D681-57D2-49BD-A618-6626E1FF4874Q37025878-051CF89E-D8DD-492D-ABD7-0890B87D83F8Q37025888-547C4EDC-518B-40B7-AF5E-49B21DCB77F8Q37608542-4F8D5E33-220D-4703-B081-277BD776657FQ37773480-1FC6F014-4EAC-46B4-9361-EE3D26661B78Q38186705-99ABBB87-4997-408B-AA53-02427FB1236AQ38192962-106EBBE0-1891-4A95-A386-C85B5720AB6EQ38665289-3E6D809D-EB95-4F94-B978-A5C6B07F1FA6Q39077987-BAB96655-0C1A-4B2D-9A44-827B31650755Q39222571-2E221A69-DF2F-4243-8573-228281B1E406Q39778911-564BEFFD-0EBA-4521-8BD3-86DED41CE457Q41828999-20AA5D84-4648-4B85-8C7F-D25CFC1C1C44Q42038959-5C23220D-CF2E-4CF8-93E1-298BC7F94CC2Q42093765-24CB45C2-0E2D-4486-899D-D3A2D89645B6Q42154556-70802AAB-734B-47B6-812F-F0AFC2B718A5Q43713315-2B54B127-D7ED-4484-9353-BB6EB3665D39Q47563473-A98CD515-1E40-44AF-8DDA-6DA85991DF90Q47587937-7CD0E390-36CA-4C86-BCF5-252FB44E353E
P2860
Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Discovery and characterization ...... in the central nervous system.
@ast
Discovery and characterization ...... in the central nervous system.
@en
type
label
Discovery and characterization ...... in the central nervous system.
@ast
Discovery and characterization ...... in the central nervous system.
@en
prefLabel
Discovery and characterization ...... in the central nervous system.
@ast
Discovery and characterization ...... in the central nervous system.
@en
P2093
P2860
P50
P356
P1476
Discovery and characterization ...... in the central nervous system.
@en
P2093
Alexander S Kane
C David Weaver
Carrie K Jones
Eric S Dawson
Evan P Lebois
J Phillip Kennedy
L Michelle Lewis
Satyawan B Jadhav
Thomas M Bridges
P2860
P304
P356
10.1021/CN900003H
P577
2010-01-01T00:00:00Z